Imugene posts another achievement: PD1-Vaxx abstract published at ASCO 2022 - Kalkine Media

Highlights

• Imugene Limited (ASX:IMU) has recently announced the publication of results from its PD1-Vaxx IMPRINTER trial in an abstract at ASCO 2022.
• The lead author of the abstract is Professor Gary Richardson OAM.
• PD1-Vaxx is being assessed in combination with atezolizumab in the Phase 1b trial.

In the latest update, Australia-based Imugene Limited (ASX:IMU) has announced the publication of the PD1-Vaxx abstract at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting. The Company informed that results from its Phase 1 PD1-Vaxx IMPRINTER trial in adults with non-small cell lung cancer (NSCLC) have been published in this abstract.

Related Article: Imugene signs a new agreement for PD1-Vaxx, wins another patent for HER-Vaxx  

Imugene’s PD1-Vaxx (IMU-201) is being developed using an active immunisation approach for treating cancers that overexpress PD-L1 by inducing the production of anti-PD-1 antibodies with a peptide epitope designed to stimulate polyclonal antibodies against PD-1.

PD1-Vaxx abstract

The abstract is titled “IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101)”.

The lead author of the abstract is Professor Gary Richardson OAM - Director of the Cabrini Institute Research & Education, Oncology Clinics Victoria, and Szalmuk Family Department of Medical Oncology.

IMPRINTER study details

Imugene’s IMPRINTER study is an ongoing open-label dose escalation study of PD1-Vaxx as monotherapy (Phase 1) or in combination with atezolizumab (Phase 1b) for patients with PD-L1 expressing NSCLC. All patients enrolled in Phase 1 of the clinical trial must have earlier received an immune checkpoint inhibitor and experienced disease progression.

The primary objective of the clinical trial is to assess the safety and tolerability of PD1-Vaxx and identify the optimal biological dose (OBD). However, the secondary objective is to evaluate the efficacy of PD1-Vaxx as monotherapy and in combination with atezolizumab.

In the study, PD1-Vaxx was administered by intramuscular (IM) injection on Day 1, Day 15, and Day 29. Dose-limiting toxicity assessment was completed after 29 days on treatment.

Do Not Miss: Imugene advances Phase 1 clinical trial of PD1-Vaxx, appoints two industry leaders

Results from Phase 1 PD1-Vaxx IMPRINTER trial

In the Phase 1 trial, four patients were enrolled into each of the three cohorts at 10 μg/dose, 50 μg/dose and 100 μg/dose of IMU-201, with no dose limiting toxicities observed.

In the 10 μg/dose cohort, one patient achieved complete response (CR) and one patient stable disease (SD). In the 50 μg/dose cohort, four patients achieved SD; and in the 100 μg/dose cohort, one patient achieved partial response (PR), and two patients achieved SD.

Within the 100 μg/dose cohort, one patient experienced an immune related pneumonitis after two administrations of IMU-201 and discontinued from study treatment.

Overall, IMU-201 observed no dose-limiting toxicity and demonstrated preliminary signs of efficacy in the Phase 1 trial. PD1-Vaxx has already proceeded to combination dose escalation, where it is being assessed in combination with atezolizumab.

Imugene shares closed the trading session at A$0.190 on 27 May 2022.

Also Read: What lies ahead for Imugene Limited (ASX:IMU) in 2022?